menveo
gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,
menactra
sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 48 microgram; meningococcal polysaccharide group y, quantity: 4 microgram; meningococcal polysaccharide group w135, quantity: 4 microgram; meningococcal polysaccharide group c, quantity: 4 microgram; meningococcal polysaccharide group a, quantity: 4 microgram - injection, solution - excipient ingredients: monobasic sodium phosphate; sodium chloride; dibasic sodium phosphate - menactra is indicated for active immunisation of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y and w-135.,menactra is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b.,menactra is not indicated for treatment of meningococcal infections.,menactra is not indicated for immunisation against diphtheria.
neisvac-c 10 µg/0.5 ml inj. susp. i.m. pre-filled syr.
pfizer sa-nv - neisseria meningitidis group c polysaccharides conjugated to tetanus toxoid as a carrier 10 - suspension for injection - 10 µg/0,5 ml - neisseria meningitidis c, polysaccharides conjugated to tetanus toxoid as a carrier - meningococcus c, purified polysaccharides antigen conjugated
trumenba
pfizer new zealand limited - neisseria meningitidis group b factor h binding protein subfamily a 0.12 mg/ml; ; neisseria meningitidis group b factor h binding protein subfamily b 0.12 mg/ml; - suspension for injection - 120 mcg/0.5ml - active: neisseria meningitidis group b factor h binding protein subfamily a 0.12 mg/ml neisseria meningitidis group b factor h binding protein subfamily b 0.12 mg/ml excipient: aluminium as aluminium phosphate histidine polysorbate 80 sodium chloride water for injection - trumenba is indicated in individuals 10 years and older for active immunisation to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.
menquadfi
pharmacy retailing (nz) ltd t/a healthcare logistics - neisseria meningitidis group a polysaccharide 10ug (conjugated to tetanus toxoid); neisseria meningitidis group c polysaccharide 10ug (conjugated to tetanus toxoid); neisseria meningitidis group w135 polysaccharide 10ug (conjugated to tetanus toxoid); neisseria meningitidis group y polysaccharide 10ug (conjugated to tetanus toxoid) - solution for injection - 0.5 ml - active: neisseria meningitidis group a polysaccharide 10ug (conjugated to tetanus toxoid) neisseria meningitidis group c polysaccharide 10ug (conjugated to tetanus toxoid) neisseria meningitidis group w135 polysaccharide 10ug (conjugated to tetanus toxoid) neisseria meningitidis group y polysaccharide 10ug (conjugated to tetanus toxoid) excipient: sodium acetate sodium chloride tetanus toxoid water for injection - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y. the use of menquadfi should be in accordance with official recommendations.
meningitec 0.5 millilitre solution for injection
nuron biotech b.v. - neisseria meningitidis serogroup c (strain c11) polysaccharide, corynebacterium diphtheriae crm197 carrier protein, aluminium phosphate - solution for injection - 0.5 millilitre - meningococcal vaccines
menjugate kit 10 microgram pdr+solv for susp for inj
gsk vaccines s.r.l. - neisseria meningitidis c, corynebacterium diphtheriae crm197 carrier protein - pdr+solv for susp for inj - 10 microgram - meningococcal vaccines
neisvac-c suspension for injection
baxter healthcare limited - neisseria meningitidis c tetanus toxoid - suspension for injection
nimenrix powder and solvent for solution for injection
pfizer private limited - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w-135 polysaccharide; neisseria meningitidis group y polysaccharide; tetanus toxoid carrier protein - injection, powder, for solution - 5 micrograms - neisseria meningitidis group a polysaccharide 5 micrograms; neisseria meningitidis group c polysaccharide 5 micrograms; neisseria meningitidis group w-135 polysaccharide 5 micrograms; neisseria meningitidis group y polysaccharide 5 micrograms; tetanus toxoid carrier protein ~44 micrograms
menjugate liquid suspension
glaxosmithkline inc - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm-197 protein - suspension - 10mcg; 25mcg - meningococcal group c oligosaccharide 10mcg; corynebacterium diphtheriae crm-197 protein 25mcg - toxoids